Company intelligence / Profile preview

Oxular Limited

Oxford, England, United Kingdom

Ownership: Private
Employees: ~20
Development stage: Phase 2

Overview

In October 2024, Oxular began dosing patients in the OXEYE phase 2 clinical trial, evaluating the safety, efficacy, and durability of OXU-001 in patients with diabetic macular edema. The trial is designed to evaluate a single suprachoroidal administration of OXU-001 over 52 weeks. Past and current trials indicate up to 12-month durability, sustained vision gain, and retinal thickness reduction.

Therapeutic areas: Ophthalmology
Modalities: Drug/device combination treatmentssustained-release formulations (Oxuspheres)
Industry: Biotech

Drug pipeline

4 assets

dexamethasone

Phase 2

Indications: Diabetic macular edema

3 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Oxular Limited.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Oxular Limited.

Explore the full profile